Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Arcus Biosciences (RCUS) is a leading biotechnology business based in the US. It opened the day at $28.72 after a previous close of $28.75. During the day the price has varied from a low of $28.46 to a high of $29.185. The latest price was $29.07 (25 minute delay). Arcus Biosciences is listed on the NYSE and employs 500 staff. All prices are listed in US Dollars.
Finder Award
Interactive Brokers
National Bank Direct Brokerage
| Open | $28.72 |
|---|---|
| High | $29.19 |
| Low | $28.46 |
| Close | $29.07 |
| Previous close | $28.75 |
| Change | $0.32 |
| Change % | 1.113% |
| Volume | 721,166 |
| 52-week range | $15.70 - $39.75 |
|---|---|
| 50-day moving average | $19.34 |
| 200-day moving average | $24.52 |
| Wall St. target price | $43.25 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-3.66 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $29.07 from 2023-03-24
| 1 week (2023-03-21) | 73.76% |
|---|---|
| 1 month (2023-02-28) | 59.64% |
| 3 months (2022-12-28) | 47.56% |
| 6 months (2022-09-28) | 8.47% |
| 1 year (2022-03-24) | -16.27% |
|---|---|
| 2 years (2021-03-26) | -11.13% |
| 3 years (2020-03-27) | 129.44% |
| 5 years (2018-03-28) | 81.46% |
| Revenue TTM | $112 million |
|---|---|
| Gross profit TTM | $-176,000,000 |
| Return on assets TTM | -11.92% |
| Return on equity TTM | -35.62% |
| Profit margin | -238.39% |
| Book value | $9.01 |
| Market capitalisation | $1.2 billion |
TTM: trailing 12 months
We're not expecting Arcus Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Arcus Biosciences's shares have ranged in value from as little as $15.7 up to $39.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Arcus Biosciences's is 0.8819. This would suggest that Arcus Biosciences's shares are less volatile than average (for this exchange).
Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L. P.
Your guide to how ETFs work and whether this type of investment is right for you.
Read more…
The best stock trading app for beginners is easy to use and offers free trades.
Read more…
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
Read more…Everything we know about the Neuraxis IPO plus information on how to buy in.
Everything we know about the Brera IPO plus information on how to buy in.
Everything we know about the TXO Energy IPO plus information on how to buy in.
Your guide to how ETFs work and whether this type of investment is right for you.
Steps to owning and managing TXG stock, with 24-hour and historical pricing before you buy.
The best stock trading app for beginners is easy to use and offers free trades.
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
An healthcare company, NFT tech developer and baby products retailer are among the IPOs expected to take place this month.
Owning a stock means you own part of a company and can potentially grow your wealth. But there is a risk of loss.
The best time to buy stocks could be right after an IPO, during expansion periods or when other investors are buying or selling.
